Who has been buying Jinjin Biopharm stock?

1 distinct insiders have filed 124 disclosed insider purchases in Jinjin Biopharm (110020), most recently on 2026-06-10. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Jinjin Biopharm have?

Jinjin Biopharm has 124 buy-side and 0 sell-side disclosures on record, covering ₩170M ($118K) in total reported value, spanning 2024-05-08 to 2026-06-10.

Where does StockDrifts get Jinjin Biopharm insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Jinjin Biopharm 110020

Company

전진바이오팜Jinjin Biopharm

Insiders

Buys

124

Total Value

₩170M ($118K)

Avg Return

-4.97%

Last Filing

2026-06-10

Jinjin Biopharm (110020) has 124 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩170M ($118K) in reported transaction value. The earliest filing StockDrifts holds for Jinjin Biopharm is dated 2024-05-08; the most recent is 2026-06-10. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -4.97%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	544	₩1,952	+2.3%	₩1M ($717)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	250	₩1,952	+2.3%	₩477K ($331)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	249	₩1,952	+2.3%	₩467K ($324)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	216	₩1,952	+2.3%	₩410K ($285)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	160	₩1,952	+2.3%	₩303K ($211)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	84	₩1,952	+2.3%	₩159K ($111)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	25	₩1,952	+2.3%	₩48K ($33)
2026-08-11	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1.1K	₩1,952	+2.3%	₩2M ($1K)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	16	₩1,972	+1.2%	₩31K ($21)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1	₩1,972	+1.2%	₩2K ($1)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	6	₩1,972	+1.2%	₩12K ($8)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1.1K	₩1,972	+1.2%	₩2M ($2K)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	904	₩1,972	+1.2%	₩2M ($1K)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	685	₩1,972	+1.2%	₩1M ($920)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	163	₩1,972	+1.2%	₩315K ($219)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	99	₩1,972	+1.2%	₩191K ($133)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	55	₩1,972	+1.2%	₩106K ($74)
2026-08-10	BUY	Market Buy	이태훈 Taehoon Lee	CEO	26	₩1,972	+1.2%	₩50K ($35)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	9	₩1,901	+5.0%	₩17K ($12)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1.1K	₩1,901	+5.0%	₩2M ($1K)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	555	₩1,901	+5.0%	₩1M ($718)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	551	₩1,901	+5.0%	₩1M ($716)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	459	₩1,901	+5.0%	₩844K ($586)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	328	₩1,901	+5.0%	₩605K ($420)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	272	₩1,901	+5.0%	₩509K ($353)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	173	₩1,901	+5.0%	₩323K ($224)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	92	₩1,901	+5.0%	₩170K ($118)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	50	₩1,901	+5.0%	₩93K ($65)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	44	₩1,901	+5.0%	₩81K ($56)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	40	₩1,901	+5.0%	₩73K ($51)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	38	₩1,901	+5.0%	₩71K ($49)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	38	₩1,901	+5.0%	₩70K ($49)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	17	₩1,901	+5.0%	₩32K ($22)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	12	₩1,901	+5.0%	₩22K ($15)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	9	₩1,901	+5.0%	₩17K ($12)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	9	₩1,901	+5.0%	₩17K ($12)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	8	₩1,901	+5.0%	₩15K ($10)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	8	₩1,901	+5.0%	₩15K ($10)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	5	₩1,901	+5.0%	₩9K ($6)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	5	₩1,901	+5.0%	₩9K ($6)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	4	₩1,901	+5.0%	₩8K ($5)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	2	₩1,901	+5.0%	₩4K ($3)
2026-08-07	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1	₩1,901	+5.0%	₩2K ($1)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	3	₩1,913	+4.3%	₩6K ($4)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	257	₩1,913	+4.3%	₩462K ($321)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	92	₩1,913	+4.3%	₩170K ($118)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	80	₩1,913	+4.3%	₩146K ($101)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	21	₩1,913	+4.3%	₩38K ($26)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	1	₩1,913	+4.3%	₩2K ($1)
2026-08-06	BUY	Market Buy	이태훈 Taehoon Lee	CEO	12	₩1,913	+4.3%	₩22K ($15)

Showing the 50 most recent of 200 filings.

Frequently asked questions

Who has been buying Jinjin Biopharm stock?: 1 distinct insiders have filed 124 disclosed insider purchases in Jinjin Biopharm (110020), most recently on 2026-06-10. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Jinjin Biopharm have?: Jinjin Biopharm has 124 buy-side and 0 sell-side disclosures on record, covering ₩170M ($118K) in total reported value, spanning 2024-05-08 to 2026-06-10.
Where does StockDrifts get Jinjin Biopharm insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Jinjin Biopharm. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.